Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. BackgroundHeart failure with preserved ejection fraction (HFpEF) disproportionately affects elderly women, with potential contributions from sex‐specific hormonal and physiological factors.
We aimed to evaluate sex‐specific prognostic differences, comorbidity impacts, and guideline‐directed medical therapy effects in elderly patients with HFpEF.MethodsRetrospective analysis of 603 patients (age ≥60 years, male: 51.6%, mean age: 79.10±9.19 years) newly diagnosed with HFpEF at Huadong Hospital, Fudan University (from July 2019 to June 2024) with follow‐up through December 2024. The primary outcome was all‐cause mortality.ResultsThe overall mortality rate was 14.2/100 person‐years (women: 15.4 versus men: 13.2).
Based on the gender and etiology phenotype classification for HFpEF, patients with types I/IV HFpEF had better survival (10.0/12.4 per 100 person‐years) versus those with types II/III/V (17.1/22.9/24.2 per 100 person‐years). Sex‐specific mortality peaks differed, with men having type V in 30.3/100 person‐years and women having type III in 28.2/100 person‐years.
Journal of the American Heart Association published a clinical update in Cardiology on 09 Jun 2026.
The item focuses on Sex‐Specific Outcomes and Treatment Responses in Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Comprehensive Single‐Center Retrospective Study.
Review the original article for the full source wording and details.